Skip to main content
SpringerLink
Log in

Hepatocellular Carcinoma in Obesity: Finding a Needle in the Haystack?

  • Chapter
  • First Online:
Obesity, Fatty Liver and Liver Cancer

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1061))

Abstract

Obesity has been implicated in the development of hepatocellular carcinoma (HCC), one of the most common malignancies worldwide with an increasing incidence in the United States. Obesity and associated metabolic disorders such as type II diabetes and the metabolic syndrome are key factors in the development of nonalcoholic fatty liver disease (NAFLD) and promote several molecular mechanisms that may contribute to hepatocarcinogenesis. The vast majority of HCC occur in cirrhotic livers, but a subgroup of patients may develop HCC in non-advanced NAFLD. While the incidence rate for noncirrhotic HCC is low, the population-attributable fraction is still significant due to the extraordinary prevalence of obesity-associated liver disease. This is a challenge since HCC surveillance cannot be provided to the large population of non-advanced NAFLD in a cost-efficient way and requires enhanced risk stratification strategies. Recent advances may offer new clinical, laboratory, and genetic biomarkers and help us meet this important public health need.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA. 2014;311:806–14.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Calzadilla Bertot L, Adams LA. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci. 2016;17

    Google Scholar 

  3. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579–91.

    Article  PubMed  CAS  Google Scholar 

  4. Basen-Engquist K, Chang M. Obesity and cancer risk: recent review and evidence. Curr Oncol Rep. 2011;13:71–6.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Vanni E, Bugianesi E. Obesity and liver cancer. Clin Liver Dis. 2014;18:191–203.

    Article  PubMed  Google Scholar 

  6. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in nonalcoholic fatty liver disease: an emerging menace. J Hepatol. 2012;56:1384–91.

    Article  PubMed  Google Scholar 

  7. Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int. 2017;37(Suppl 1):81–4.

    Article  PubMed  Google Scholar 

  8. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.

    Article  PubMed  Google Scholar 

  9. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27:1485–91.

    Article  PubMed  PubMed Central  Google Scholar 

  10. White DL, Thrift AP, Kanwal F, Davila J, El-Serag HB. Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012. Gastroenterology. 2016

    Google Scholar 

  11. American Cancer Society. Cancer Statistics Center. 2018. https://cancerstatisticscenter.cancer.org/#!/cancer-site/Liver%20and%20intrahepatic%20bile%20duct. Accessed 27 Mar 2018.

  12. El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 2014;60:1767–75.

    Article  PubMed  Google Scholar 

  13. Charlton M. Cirrhosis and liver failure in nonalcoholic fatty liver disease: molehill or mountain? Hepatology. 2008;47:1431–3.

    Article  PubMed  Google Scholar 

  14. Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med. 2016;67:103–17.

    Article  PubMed  CAS  Google Scholar 

  15. Batty GD, Shipley MJ, Jarrett RJ, Breeze E, Marmot MG, Smith GD. Obesity and overweight in relation to organ-specific cancer mortality in London (UK): findings from the original Whitehall study. Int J Obes. 2005;29:1267–74.

    Article  CAS  Google Scholar 

  16. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–38.

    Article  PubMed  Google Scholar 

  17. Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer. 2007;97:1005–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012;35:2402–11.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Turati F, Talamini R, Pelucchi C, Polesel J, Franceschi S, Crispo A, et al. Metabolic syndrome and hepatocellular carcinoma risk. Br J Cancer. 2013;108:222–08.

    Article  PubMed  CAS  Google Scholar 

  20. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011;54:463–71.

    Article  PubMed  Google Scholar 

  21. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004;126:460–8.

    Article  PubMed  Google Scholar 

  22. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006;4:369–80.

    Article  PubMed  Google Scholar 

  23. Wang P, Kang D, Cao W, Wang Y, Liu Z. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2012;28:109–22.

    Article  PubMed  CAS  Google Scholar 

  24. Welzel TM, Graubard BI, Quraishi S, Zeuzem S, Davila JA, El-Serag HB, et al. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol. 2013;108:1314–21.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Makarova-Rusher OV, Altekruse SF, McNeel TS, Ulahannan S, Duffy AG, Graubard BI, et al. Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. Cancer. 2016;122:1757–65.

    Article  PubMed  Google Scholar 

  26. Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol. 2007;102:399–408.

    Article  PubMed  CAS  Google Scholar 

  27. Kallwitz ER, Herdegen J, Madura J, Jakate S, Cotler SJ. Liver enzymes and histology in obese patients with obstructive sleep apnea. J Clin Gastroenterol. 2007;41:918–21.

    Article  PubMed  CAS  Google Scholar 

  28. Anty R, Dahman M, Iannelli A, Gual P, Staccini-Myx A, Amor IB, et al. Bariatric surgery can correct iron depletion in morbidly obese women: a link with chronic inflammation. Obes Surg. 2008;18:709–14.

    Article  PubMed  Google Scholar 

  29. Mathurin P, Hollebecque A, Arnalsteen L, Buob D, Leteurtre E, Caiazzo R, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology. 2009;137:532–40.

    Article  PubMed  CAS  Google Scholar 

  30. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.

    Article  PubMed  Google Scholar 

  31. Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 2015;62:1723.

    Article  PubMed  CAS  Google Scholar 

  32. Sanyal A, Poklepovic A, Moyneur E, Barghout V. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin. 2010;26:2183–91.

    Article  PubMed  CAS  Google Scholar 

  33. Dyson JK, McPherson S, Anstee QM. Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. J Clin Pathol. 2013;66:1033–45.

    Article  PubMed  CAS  Google Scholar 

  34. Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology. 2014;59:2188–95.

    Article  PubMed  Google Scholar 

  35. Hardy T, Oakley F, Anstee QM, Day CP. Nonalcoholic fatty liver disease: pathogenesis and disease spectrum. Annu Rev Pathol. 2016;11:451.

    Article  PubMed  CAS  Google Scholar 

  36. Schutte K, Schulz C, Poranzke J, Antweiler K, Bornschein J, Bretschneider T, et al. Characterization and prognosis of patients with hepatocellular carcinoma (HCC) in the non-cirrhotic liver. BMC Gastroenterol. 2014;14:117.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Mittal S, El-Serag HB, Sada YH, Kanwal F, Duan Z, Temple S, et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2016;14:124–31. e121

    Article  PubMed  CAS  Google Scholar 

  38. Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, Imai Y, et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011;9:428–33.

    Article  PubMed  Google Scholar 

  39. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51:1972–8.

    Article  PubMed  Google Scholar 

  40. Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Tokushige K, et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol. 2009;44(Suppl 19):89–95.

    Article  PubMed  Google Scholar 

  41. Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology. 2006;43:682–9.

    Article  PubMed  Google Scholar 

  42. Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology. 2011;54:1208–16.

    Article  PubMed  Google Scholar 

  43. Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T, et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol. 2012;107:253–61.

    Article  PubMed  CAS  Google Scholar 

  44. Arase Y, Kobayashi M, Suzuki F, Suzuki Y, Kawamura Y, Akuta N, et al. Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients. Hepatol Res. 2012;42:264–72.

    Article  PubMed  Google Scholar 

  45. Volzke H. Multicausality in fatty liver disease: is there a rationale to distinguish between alcoholic and non-alcoholic origin? World J Gastroenterol. 2012;18:3492–501.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Schutte K, Kipper M, Kahl S, Bornschein J, Gotze T, Adolf D, et al. Clinical characteristics and time trends in etiology of hepatocellular cancer in Germany. Digestion. 2013;87:147–59.

    Article  PubMed  Google Scholar 

  47. Dyson J, Jaques B, Chattopadyhay D, Lochan R, Graham J, Das D, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol. 2014;60:110–7.

    Article  PubMed  Google Scholar 

  48. Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S, Tiribelli C, et al. Clinical patterns of hepatocellular carcinoma (HCC) in non alcoholic fatty liver disease (NAFLD): a multicenter prospective study. Hepatology. 2015

    Google Scholar 

  49. Dunn W, Xu R, Schwimmer JB. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology. 2008;47:1947–54.

    Article  PubMed  Google Scholar 

  50. Nair S, Mason A, Eason J, Loss G, Perrillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology. 2002;36:150–5.

    Article  PubMed  Google Scholar 

  51. Pais R, Lebray P, Rousseau G, Charlotte F, Esselma G, Savier E, et al. Nonalcoholic fatty liver disease increases the risk of hepatocellular carcinoma in patients with alcohol-associated cirrhosis awaiting liver transplants. Clin Gastroenterol Hepatol. 2015;13:992–9.

    Article  PubMed  Google Scholar 

  52. N’Kontchou G, Paries J, Htar MT, Ganne-Carrie N, Costentin L, Grando-Lemaire V, et al. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis. Clin Gastroenterol Hepatol. 2006;4:1062–8.

    Article  PubMed  Google Scholar 

  53. Edenvik P, Davidsdottir L, Oksanen A, Isaksson B, Hultcrantz R, Stal P. Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice? Liver Int. 2015;35:1862–71.

    Article  PubMed  Google Scholar 

  54. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology. 2008;135:111–21.

    Article  PubMed  CAS  Google Scholar 

  55. Chan AW, Wong GL, Chan HY, Tong JH, Yu YH, Choi PC, et al. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. J Gastroenterol Hepatol. 2016;32(3):667–76.

    Article  PubMed  CAS  Google Scholar 

  56. Tsai IT, Wang CP, Yu TH, Lu YC, Lin CW, Lu LF, et al. Circulating visfatin level is associated with hepatocellular carcinoma in chronic hepatitis B or C virus infection. Cytokine. 2017;90:54–9.

    Article  PubMed  CAS  Google Scholar 

  57. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 2002;31:339–46.

    Article  PubMed  CAS  Google Scholar 

  58. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6:674–87.

    Article  PubMed  CAS  Google Scholar 

  59. Aravalli RN, Cressman EN, Steer CJ. Cellular and molecular mechanisms of hepatocellular carcinoma: an update. Arch Toxicol. 2013;87:227–47.

    Article  PubMed  CAS  Google Scholar 

  60. Zhang DY, Friedman SL. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology. 2012;56:769–75.

    Article  PubMed  CAS  Google Scholar 

  61. Breuhahn K, Schirmacher P. Signaling networks in human hepatocarcinogenesis – novel aspects and therapeutic options. Prog Mol Biol Transl Sci. 2010;97:251–77.

    Article  PubMed  CAS  Google Scholar 

  62. Dufour JF, Johnson P. Liver cancer: from molecular pathogenesis to new therapies summary of the EASL single topic conference. J Hepatol. 2010;52:296–304.

    Article  PubMed  CAS  Google Scholar 

  63. Goossens N, Sun X, Hoshida Y. Molecular classification of hepatocellular carcinoma: potential therapeutic implications. Hepat Oncol. 2015;2:371–9.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology. 2015;149:1226–39. e1224

    Article  PubMed  CAS  Google Scholar 

  65. Karagozian R, Derdak Z, Baffy G. Obesity-associated mechanisms of hepatocarcinogenesis. Metabolism. 2014;63:607–17.

    Article  PubMed  CAS  Google Scholar 

  66. Sanna C, Rosso C, Marietti M, Bugianesi E. Non-alcoholic fatty liver disease and extra-hepatic cancers. Int J Mol Sci. 2016;17(5):717.

    Article  PubMed Central  CAS  Google Scholar 

  67. Tilg H, Moschen AR. Mechanisms behind the link between obesity and gastrointestinal cancers. Best Pract Res Clin Gastroenterol. 2014;28:599–610.

    Article  PubMed  CAS  Google Scholar 

  68. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414:799–806.

    Article  PubMed  CAS  Google Scholar 

  69. Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, Goldstein JL. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell. 2000;6:77–86.

    Article  PubMed  CAS  Google Scholar 

  70. Brown MS, Goldstein JL. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab. 2008;7:95–6.

    Article  PubMed  CAS  Google Scholar 

  71. Eissing L, Scherer T, Todter K, Knippschild U, Greve JW, Buurman WA, et al. De novo lipogenesis in human fat and liver is linked to ChREBP-beta and metabolic health. Nat Commun. 2013;4:1528.

    Article  PubMed  CAS  Google Scholar 

  72. Lee JS, Mendez R, Heng HH, Yang ZQ, Zhang K. Pharmacological ER stress promotes hepatic lipogenesis and lipid droplet formation. Am J Transl Res. 2012;4:102–13.

    PubMed  PubMed Central  CAS  Google Scholar 

  73. Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer. 2011;11:886–95.

    Article  PubMed  CAS  Google Scholar 

  74. Kim KW, Bae SK, Lee OH, Bae MH, Lee MJ, Park BC. Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Cancer Res. 1998;58:348–51.

    PubMed  CAS  Google Scholar 

  75. Tanaka S, Mohr L, Schmidt EV, Sugimachi K, Wands JR. Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes. Hepatology. 1997;26:598–604.

    Article  PubMed  CAS  Google Scholar 

  76. Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer. 2010;116:1938–46.

    Article  PubMed  Google Scholar 

  77. Brunt EM. What’s in a Name? Hepatology. 2009;50:663–7.

    Article  PubMed  Google Scholar 

  78. Unger RH, Clark GO, Scherer PE, Orci L. Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim Biophys Acta. 2010;1801:209–14.

    Article  PubMed  CAS  Google Scholar 

  79. Puri P, Mirshahi F, Cheung O, Natarajan R, Maher JW, Kellum JM, et al. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology. 2008;134:568–76.

    Article  PubMed  CAS  Google Scholar 

  80. Cazanave SC, Gores GJ. Mechanisms and clinical implications of hepatocyte lipoapoptosis. Clin Lipidol. 2010;5:71–85.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. 2004;306:457–61.

    Article  PubMed  CAS  Google Scholar 

  82. Vinciguerra M, Carrozzino F, Peyrou M, Carlone S, Montesano R, Benelli R, et al. Unsaturated fatty acids promote hepatoma proliferation and progression through downregulation of the tumor suppressor PTEN. J Hepatol. 2009;50:1132–41.

    Article  PubMed  CAS  Google Scholar 

  83. Joshi-Barve S, Barve SS, Amancherla K, Gobejishvili L, Hill D, Cave M, et al. Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes. Hepatology. 2007;46:823–30.

    Article  PubMed  CAS  Google Scholar 

  84. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer. 2003;3:276–85.

    Article  PubMed  CAS  Google Scholar 

  85. Haslam DW, James WP. Obesity. Lancet. 2005;366:1197–209.

    Article  PubMed  Google Scholar 

  86. Virtue S, Vidal-Puig A. Adipose tissue expandability, lipotoxicity and the metabolic syndrome – an allostatic perspective. Biochim Biophys Acta. 2010;1801:338–49.

    Article  PubMed  CAS  Google Scholar 

  87. Sun K, Kusminski CM, Scherer PE. Adipose tissue remodeling and obesity. J Clin Invest. 2011;121:2094–101.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  88. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007;132:2169–80.

    Article  PubMed  CAS  Google Scholar 

  89. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860–7.

    Article  PubMed  CAS  Google Scholar 

  90. He Q, Gao Z, Yin J, Zhang J, Yun Z, Ye J. Regulation of HIF-1{alpha} activity in adipose tissue by obesity-associated factors: adipogenesis, insulin, and hypoxia. Am J Physiol Endocrinol Metab. 2011;300:E877–85.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  91. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology. 2009;50:957–69.

    Article  PubMed  CAS  Google Scholar 

  92. Stickel F, Hellerbrand C. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut. 2010;59:1303–7.

    Article  PubMed  CAS  Google Scholar 

  93. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Investig. 2006;116:1784–92.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  94. Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev. 2012;33:547–94.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  95. Duan XF, Tang P, Li Q, Yu ZT. Obesity, adipokines and hepatocellular carcinoma. Int J Cancer. 2013;133:1776–83.

    Article  PubMed  CAS  Google Scholar 

  96. Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013;13:800–12.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  97. Quigley EM, Abu-Shanab A, Murphy EF, Stanton C, Monsour HP Jr. The metabolic role of the microbiome: implications for NAFLD and the metabolic syndrome. Semin Liver Dis. 2016;36:312–6.

    Article  PubMed  CAS  Google Scholar 

  98. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371:838–51.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  99. Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest. 2011;121:2126–32.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  100. Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fung SK, Fischer SE, et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013;58:120–7.

    Article  CAS  PubMed  Google Scholar 

  101. Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, Mederacke I, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell. 2012;21:504–16.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  102. Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 2013;499:97–101.

    Article  PubMed  CAS  Google Scholar 

  103. Fuchs CD, Traussnigg SA, Trauner M. Nuclear receptor modulation for the treatment of nonalcoholic fatty liver disease. Semin Liver Dis. 2016;36:69–86.

    Article  PubMed  CAS  Google Scholar 

  104. Baffy G. The impact of network medicine in gastroenterology and hepatology. Clin Gastroenterol Hepatol. 2013;11:1240–4.

    Article  PubMed  Google Scholar 

  105. Moylan CA, Pang H, Dellinger A, Suzuki A, Garrett ME, Guy CD, et al. Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. Hepatology. 2014;59:471–82.

    Article  PubMed  CAS  Google Scholar 

  106. Clarke JD, Novak P, Lake AD, Shipkova P, Aranibar N, Robertson D, et al. Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease. Dig Dis Sci. 2014;59:365–74.

    Article  PubMed  CAS  Google Scholar 

  107. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113–21.

    Article  PubMed  Google Scholar 

  108. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–73.

    Article  PubMed  CAS  Google Scholar 

  109. Kaswala DH, Lai M, Afdhal NH. Fibrosis assessment in nonalcoholic fatty liver disease (NAFLD) in 2016. Dig Dis Sci. 2016;61:1356–64.

    Article  PubMed  CAS  Google Scholar 

  110. Buzzetti E, Lombardi R, De Luca L, Tsochatzis EA. Noninvasive assessment of fibrosis in patients with nonalcoholic fatty liver disease. Int J Endocrinol. 2015;2015:343828.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  111. Asrani SK. Incorporation of noninvasive measures of liver fibrosis into clinical practice: diagnosis and prognosis. Clin Gastroenterol Hepatol. 2015;13:2190–204.

    Article  PubMed  Google Scholar 

  112. Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010;59:969–74.

    Article  PubMed  Google Scholar 

  113. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015;13:643–654 e641–649; quiz e639–640.

    Article  Google Scholar 

  114. McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62:1148–55.

    Article  PubMed  Google Scholar 

  115. Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol. 2013;59:550–6.

    Article  PubMed  CAS  Google Scholar 

  116. Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology. 2010;52:132–41.

    Article  PubMed  Google Scholar 

  117. Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med. 2003;139:46–50.

    Article  PubMed  CAS  Google Scholar 

  118. Sherman M. Surveillance for hepatocellular carcinoma. Semin Oncol. 2001;28:450–9.

    Article  PubMed  CAS  Google Scholar 

  119. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology. 2003;37:1114–21.

    Article  PubMed  CAS  Google Scholar 

  120. Voiculescu M, Nanau RM, Neuman MG. Non-invasive biomarkers in non-alcoholic steatohepatitis-induced hepatocellular carcinoma. J Gastrointestin Liver Dis. 2014;23:425–9.

    PubMed  Google Scholar 

  121. Miao R, Luo H, Zhou H, Li G, Bu D, Yang X, et al. Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis. J Hepatol. 2014;61:840–9.

    Article  PubMed  CAS  Google Scholar 

  122. Jin GZ, Li Y, Cong WM, Yu H, Dong H, Shu H, et al. iTRAQ-2DLC-ESI-MS/MS based identification of a new set of immunohistochemical biomarkers for classification of dysplastic nodules and small hepatocellular carcinoma. J Proteome Res. 2011;10:3418–28.

    Article  PubMed  CAS  Google Scholar 

  123. Nishida N, Kudo M, Nishimura T, Arizumi T, Takita M, Kitai S, et al. Unique association between global DNA hypomethylation and chromosomal alterations in human hepatocellular carcinoma. PLoS One. 2013;8:e72312.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  124. Llovet JM, Chen Y, Wurmbach E, Roayaie S, Fiel MI, Schwartz M, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology. 2006;131:1758–67.

    Article  PubMed  CAS  Google Scholar 

  125. Gori M, Arciello M, Balsano C. MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma. Biomed Res Int. 2014;2014:741465.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  126. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.

    Article  CAS  PubMed  Google Scholar 

  127. Mohr AM, Mott JL. Overview of microRNA biology. Semin Liver Dis. 2015;35:3–11.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  128. Wang XW, Heegaard NH, Orum H. MicroRNAs in liver disease. Gastroenterology. 2012;142:1431–43.

    Article  PubMed  CAS  Google Scholar 

  129. Arner P, Kulyte A. MicroRNA regulatory networks in human adipose tissue and obesity. Nat Rev Endocrinol. 2015;11:276–88.

    Article  PubMed  CAS  Google Scholar 

  130. Sobolewski C, Calo N, Portius D, Foti M. MicroRNAs in fatty liver disease. Semin Liver Dis. 2015;35:12–25.

    Article  PubMed  CAS  Google Scholar 

  131. Finch ML, Marquardt JU, Yeoh GC, Callus BA. Regulation of microRNAs and their role in liver development, regeneration and disease. Int J Biochem Cell Biol. 2014;54:288–303.

    Article  PubMed  CAS  Google Scholar 

  132. Afonso MB, Rodrigues PM, Simao AL, Castro RE. Circulating microRNAs as potential biomarkers in non-alcoholic fatty liver disease and hepatocellular carcinoma. J Clin Med. 2016;5(3).

    Article  PubMed Central  CAS  Google Scholar 

  133. Cheng G. Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev. 2015;81:75–93.

    Article  PubMed  CAS  Google Scholar 

  134. Arrese M, Eguchi A, Feldstein AE. Circulating microRNAs: emerging biomarkers of liver disease. Semin Liver Dis. 2015;35:43–54.

    Article  PubMed  CAS  Google Scholar 

  135. Csak T, Bala S, Lippai D, Satishchandran A, Catalano D, Kodys K, et al. microRNA-122 regulates hypoxia-inducible factor-1 and vimentin in hepatocytes and correlates with fibrosis in diet-induced steatohepatitis. Liver Int. 2015;35:532–41.

    Article  PubMed  CAS  Google Scholar 

  136. Pirola CJ, Fernandez Gianotti T, Castano GO, Mallardi P, San Martino J. Mora Gonzalez Lopez Ledesma M, et al. circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut. 2015;64:800–12.

    Article  PubMed  CAS  Google Scholar 

  137. Ye H, Liu W. Transcriptional networks implicated in human nonalcoholic fatty liver disease. Mol Gen Genomics. 2015; 290:1793–804.

    Article  PubMed  CAS  Google Scholar 

  138. Bahn JH, Zhang Q, Li F, Chan TM, Lin X, Kim Y, et al. The landscape of microRNA, Piwi-interacting RNA, and circular RNA in human saliva. Clin Chem. 2015;61:221–30.

    Article  PubMed  CAS  Google Scholar 

  139. Iwasaki YW, Siomi MC, Siomi H. PIWI-interacting RNA: its biogenesis and functions. Annu Rev Biochem. 2015;84:405–33.

    Article  PubMed  CAS  Google Scholar 

  140. Rizzo F, Rinaldi A, Marchese G, Coviello E, Sellitto A, Cordella A, et al. Specific patterns of PIWI-interacting small noncoding RNA expression in dysplastic liver nodules and hepatocellular carcinoma. Oncotarget. 2016;7:54650–61.

    Article  PubMed  PubMed Central  Google Scholar 

  141. Shariff MI, Gomaa AI, Cox IJ, Patel M, Williams HR, Crossey MM, et al. Urinary metabolic biomarkers of hepatocellular carcinoma in an Egyptian population: a validation study. J Proteome Res. 2011;10:1828–36.

    Article  PubMed  CAS  Google Scholar 

  142. Pearson TA, Manolio TA. How to interpret a genome-wide association study. JAMA. 2008;299:1335–44.

    Article  PubMed  CAS  Google Scholar 

  143. Brown PO, Botstein D. Exploring the new world of the genome with DNA microarrays. Nat Genet. 1999;21:33–7.

    Article  PubMed  CAS  Google Scholar 

  144. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545–50.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  145. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461–5.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  146. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology. 2011;53:1883–94.

    Article  CAS  PubMed  Google Scholar 

  147. Kozlitina J, Smagris E, Stender S, Nordestgaard BG, Zhou HH, Tybjaerg-Hansen A, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2014;46:352–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  148. Miele L, Beale G, Patman G, Nobili V, Leathart J, Grieco A, et al. The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology. 2008;135:282–91 e281.

    Article  PubMed  CAS  Google Scholar 

  149. Valenti L, Rametta R, Dongiovanni P, Motta BM, Canavesi E, Pelusi S, et al. The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease. PLoS One. 2012;7:e48804.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  150. Dongiovanni P, Romeo S, Valenti L. Genetic factors in the pathogenesis of nonalcoholic fatty liver and steatohepatitis. Biomed Res Int. 2015;2015:460190.

    Article  CAS  Google Scholar 

  151. Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis. 2010;30:3–16.

    Article  PubMed  CAS  Google Scholar 

  152. Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol. 2003;98:679–90.

    Article  PubMed  Google Scholar 

  153. Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with child-Pugh class a cirrhosis. Am J Med. 1996;101:422–34.

    Article  PubMed  CAS  Google Scholar 

  154. European Association For The Study Of The L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.

    Article  Google Scholar 

  155. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the study of the liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439–74.

    Article  PubMed  PubMed Central  Google Scholar 

  156. Mittal S, Sada YH, El-Serag HB, Kanwal F, Duan Z, Temple S, et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol. 2015;13:594–601 e591.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, VA Boston Healthcare System and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    György Baffy

Authors
  1. György Baffy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to György Baffy .

Editor information

Editors and Affiliations

  1. Institute of Digestive Disease and Department of Medicine & Therapeutics State Key Laboratory of Digestive Disease LKS Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, Hong Kong

    Jun Yu

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Baffy, G. (2018). Hepatocellular Carcinoma in Obesity: Finding a Needle in the Haystack?. In: Yu, J. (eds) Obesity, Fatty Liver and Liver Cancer. Advances in Experimental Medicine and Biology, vol 1061. Springer, Singapore. https://doi.org/10.1007/978-981-10-8684-7_6

Download citation

Publish with us

Policies and ethics

Search

Navigation